Home
Resources
Publications
Autoimmune Thrombocytopenia: Current Treatment Options in Adults With a Focus on Novel Drugs

Autoimmune Thrombocytopenia: Current Treatment Options in Adults With a Focus on Novel Drugs

Michał Witkowski, Magdalena Witkowska, Tadeusz Robak

Eur J Haematol. 2019 Dec;103(6):531-541.

PMID: 31449692

Abstract:

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by platelet destruction and reduced platelet production resulting in decreased platelet level and an increased risk of bleeding. Based on the immunologic mechanism of ITP, front-line standard therapy consists of corticosteroids and intravenous immunoglobulins (IVIG). If patients do not respond to the first-line treatment, or if continuous therapy is required, the disorder is called refractory ITP, and second-line therapy is indicated. This treatment may consist of rituximab, thrombopoietin receptor agonists, splenectomy, or cytotoxic drugs. Despite significant advances, many patients do not respond to any the treatments listed below, and new treatment options need to be developed for this relapsed and refractory group. Recent clinical studies have indicated promising outcomes for novel drugs, either as single agents or in combination with traditional drugs. This review discusses the latest and the most promising novel drugs for ITP in adults.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP479414	Indirubin		479-41-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: